Pelargonium sidoides, commonly known by its traditional name Umckaloabo, is a South African medicinal plant with a long history of use for respiratory complaints. The most widely studied preparation is the standardized root extract EPs 7630, which has been the subject of multiple clinical trials. Research suggests that this extract may help reduce the severity and duration of symptoms associated with acute upper respiratory tract infections, including the common cold, bronchitis, sore throat, and sinus congestion. Studies indicate that its potential benefits may involve supporting the body's natural immune response while also offering mild antibacterial properties. While the evidence is promising, particularly for acute bronchitis in adults and children, ongoing research continues to clarify its full range of effects and optimal applications.
Compare this supplementResearch suggests that Pelargonium sidoides extract (commonly marketed as Umckaloabo, standardized as EPs 7630) may h...
View studies →Research suggests that Pelargonium sidoides extract EPs 7630 (Umckaloabo) has meaningful clinical support for relievi...
View studies →Research suggests that Pelargonium sidoides extract (commonly known as EPs 7630 or Umckaloabo) may help relieve sore ...
View studies →Research suggests that Pelargonium sidoides extract (commonly sold as Umckaloabo or EPs 7630) may offer some benefit ...
View studies →These are commonly referenced dosage ranges for this supplement. They are not medical recommendations. Always consult a healthcare provider before supplementing.
| Form | Dose range | Frequency | Studied for | Source |
|---|---|---|---|---|
| Extract | 30 mg | Three times daily | Acute bronchitis and upper respiratory tract infections in adults | Common in clinical trials using EPs 7630 standardized extract |
| Extract | 20–30 mg | Three times daily | Sinusitis and sinus congestion relief | Based on RCTs evaluating acute sinusitis outcomes |
| Extract | 10–20 mg | Three times daily | Sore throat and common cold symptom relief in children | Common in pediatric clinical trials using standardized EPs 7630 extract |
| Liquid | 1.5 ml | Three times daily | Acute bronchitis and respiratory infections in adults | Based on RCTs using EPs 7630 liquid formulation |
| Liquid | 1 ml | Three times daily | Acute bronchitis and respiratory infections in children (6–12 years) | Pediatric dosing from clinical trials using EPs 7630 |
| Liquid | 0.5 ml | Three times daily | Acute bronchitis and respiratory infections in young children (1–5 years) | Pediatric dosing from clinical trials using EPs 7630 |